GeneDx Holdings Corp. (WGS)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
63. 61
-6.61
-9.4133%
$
2.01B Market Cap
- P/E Ratio
- Div Yield
644,400 Volume
0 Eps
$ 70.22
Previous Close 
Want to track WGS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?
Does GeneDx Holdings Corp. (WGS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks | 2 years ago
All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 2 years ago
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers, growing 96% in the first quarter. Increasing acceptance and coverage by major commercial payers and Medicaid for exome and genome testing.
Seekingalpha | 2 years ago
2026 © Marketlog. All Rights Reserved.
